Scholarlink

Purpose <p>Targeted therapies have improved survival in human epidermal growth factor receptor 2 positive breast cancer (HER2 + BC). However, patients over 75&#xa0;years of age are often excluded from clinical trials of anti-HER2 therapies, and it is unclear to what extent they receive these treatments in routine care. To address this, we examined age-related patterns of anti-HER2 therapy use in real-world clinical practice in Norway.</p> Methods <p>In a nationwide registry-based cohort, we identified women diagnosed with stage I-III HER2 + BC during 2012–2021. We investigated treatment patterns using descriptive statistics and estimated the direct effect of age on anti-HER2 therapy use by Poisson regression.</p> Results <p>Among 3526 women with HER2 + BC, anti-HER2 therapy use was consistently high (83–95%) in those under 75&#xa0;years, decreased to 60% at ages 75–79, and declined further with advancing age to 8% at ≥ 90&#xa0;years. Neoadjuvant anti-HER2 therapy also decreased with age (from 24% in patients under 75 to 12% in patients over 75&#xa0;years). Accounting for cancer characteristics, comorbidities, polypharmacy, and socio-economic factors, older patients had reduced likelihood of receiving any anti-HER2 therapy compared with patients younger than 55 (RR 0.75, 95% CI 0.66–0.85, p &lt; 0.001, at age 75–84 and RR 0.21, 95% CI 0.11–0.41, p &lt; 0.001, at age 85 +).</p> Conclusions <p>Anti-HER2 therapy use declined substantially after the age of 75 even when accounting for comorbidities and polypharmacy. Chronological age appears important in planning treatment for patients with HER2 + BC. Specific guidelines pertaining to older patients with HER2 + BC are needed to avoid potential undertreatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • S. Hjorth,
  • K. F. Vandraas,
  • C. B. Trewin-Nybråten,
  • E. Botteri,
  • G. Ursin,
  • B. K. Andreassen,
  • N. C. Støer

摘要

Purpose

Targeted therapies have improved survival in human epidermal growth factor receptor 2 positive breast cancer (HER2 + BC). However, patients over 75 years of age are often excluded from clinical trials of anti-HER2 therapies, and it is unclear to what extent they receive these treatments in routine care. To address this, we examined age-related patterns of anti-HER2 therapy use in real-world clinical practice in Norway.

Methods

In a nationwide registry-based cohort, we identified women diagnosed with stage I-III HER2 + BC during 2012–2021. We investigated treatment patterns using descriptive statistics and estimated the direct effect of age on anti-HER2 therapy use by Poisson regression.

Results

Among 3526 women with HER2 + BC, anti-HER2 therapy use was consistently high (83–95%) in those under 75 years, decreased to 60% at ages 75–79, and declined further with advancing age to 8% at ≥ 90 years. Neoadjuvant anti-HER2 therapy also decreased with age (from 24% in patients under 75 to 12% in patients over 75 years). Accounting for cancer characteristics, comorbidities, polypharmacy, and socio-economic factors, older patients had reduced likelihood of receiving any anti-HER2 therapy compared with patients younger than 55 (RR 0.75, 95% CI 0.66–0.85, p < 0.001, at age 75–84 and RR 0.21, 95% CI 0.11–0.41, p < 0.001, at age 85 +).

Conclusions

Anti-HER2 therapy use declined substantially after the age of 75 even when accounting for comorbidities and polypharmacy. Chronological age appears important in planning treatment for patients with HER2 + BC. Specific guidelines pertaining to older patients with HER2 + BC are needed to avoid potential undertreatment.